New partnership leverages Google’s infrastructure and artificial intelligence capabilities.
Medable has announced a collaboration with Google Cloud to bring its Digital and Decentralized Clinical Trial Platform to Google Cloud Marketplace. Customers of Medable will benefit from Google’s infrastructure and artificial intelligence capabilities with accelerated operations in clinical trial design, deployment, and management.1
In a press release, Michelle Longmire, MD co-founder and CEO of Medable said, “This alliance provides life sciences companies with Medable’s cutting-edge clinical development technology powered by Google Cloud through Google Cloud Marketplace. The collaboration will enable scaled and seamless adoption of Medable solutions by Google Cloud users, providing life sciences companies with platform capabilities proven to improve patient access to trials and accelerate critical development efforts, globally.”
In addition to its Digital and Decentralized Clinical Trial Platform, Medable’s newly launched Studio will integrate seamlessly with Google Cloud Marketplace.
“Bringing Medable’s platform to Google Cloud Marketplace will help customers quickly deploy, manage, and expand their use of the AI-driven clinical trial platform on Google Cloud's trusted, global infrastructure," Dai Vu, managing director, marketplace & ISV GTM programs at Google Cloud, said in the press release.
Medable Studio was introduced earlier in August. The application offers customers an all-in-one solution for electronic clinical outcome assessment (eCOA) management. It has capabilities in configuration, translation, and validation throughout the eCOA launch process. Customers of Studio can choose between self-service, full-service, or a combination of options.2
“Medable Studio upends the traditional study build/test/launch process by streamlining it using intelligence and automation,” Tim Smith, chief technology officer and co-founder, Medable, said in an earlier press release. “With Medable Studio, timelines shift from weeks and months to just days. Customers described Studio as a quantum leap in speed, scale, and quality, and it empowers sponsors with complete visibility and control over the entire process.”
Functions of Studio include:
In the press release, Longmire added, “This is just the start to transforming how evidence is generated. Medable Studio is where trial teams go to create. It allows for greater scalability, efficiency gains, and better, protocol-fit science. Studio will set new benchmarks for trial execution and ultimately advance our mission to enable effective therapies to reach patients faster by reducing trial start-up timelines and cost.”
1. Medable Joins Forces with Google Cloud to Deliver Digital Clinical Trials Technology on Google Cloud Marketplace. News release. Medable. October 30, 2024. Accessed November 1, 2024. https://www.businesswire.com/news/home/20241030519844/en/Medable-Joins-Forces-with-Google-Cloud-to-Deliver-Digital-Clinical-Trials-Technology-on-Google-Cloud-Marketplace
2. New Medable Studio Empowers Sponsors to Launch eCOA Solutions Into Clinical Trials With Unparalleled Control and Efficiency. News release. Medable. August 14, 2024. Accessed November 1, 2024. https://www.businesswire.com/news/home/20240814443065/en/New-Medable-Studio-Empowers-Sponsors-to-Launch-eCOA-Solutions-Into-Clinical-Trials-With-Unparalleled-Control-and-Efficiency
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Phase III MOVe-NOW Trial to Evaluate New Lagevrio Formulation Targeting High-Risk COVID-19 Patients
December 6th 2024Merck and Ridgeback Biotherapeutics have launched the Phase III MOVe-NOW trial to evaluate a new, streamlined formulation of Lagevrio (molnupiravir) for treating non-hospitalized COVID-19 patients at high risk of severe disease progression who are unable to use other antiviral therapies.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Phase II Piranga Trial Shows Promise of Xalnesiran Combination for Hepatitis B Treatment
December 5th 2024Phase II Piranga trial found that the combination of xalnesiran and an immunomodulator effectively reduced hepatitis B surface antigen (HBsAg) levels, but highlighted challenges in response durability and efficacy in patients with high HBsAg levels.